3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Melanoma
23
Multiple Myeloma
9
Colorectal Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Thyroid Neoplasms
8
Glioma
8
Neoplasm Metastasis
7
Hematologic Neoplasms
6
Thyroid Carcinoma, Anaplastic
5
Lymphoma
5
Thyroid Cancer, Papillary
4
Pancreatic Neoplasms
4
Neurofibromatosis 1
4
Neoplasms
4
Lung Neoplasms
3
Brain Neoplasms
3
Astrocytoma
3
Adenocarcinoma, Follicular
3
Skin Neoplasms
2
Recurrence
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neurofibroma, Plexiform
2
Leukemia, Myelomonocytic, Juvenile
2
Histiocytosis, Langerhans-Cell
2
Glioblastoma
2
Colonic Neoplasms
2
Advanced Solid Tumors
2
Uveal Melanoma
1
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
trametinib
×
1 year
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled